Hematology
Latest News
Advertisement
Latest Videos
CME Content
Advertisement
More News
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences, discussed the company’s trial design presentation at ASCO’s 2025 meeting.
KITE-363 shows promising results in treating relapsed/refractory large B-cell lymphoma, with high response rates and manageable adverse events.
Review top news and interview highlights from the week ending May 30, 2025.
The chief executive officer and cofounder of March Biosciences discussed the company’s trial design presentation at ASCO’s 2025 meeting.
In Episode 4 of ImmunoLogic, Caroline Diorio, MD, FRCPC, FAAP, discussed her research on adverse events associated with cell therapy.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Review top news and interview highlights from the week ending May 23, 2025.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Review top news and interview highlights from the week ending May 16, 2025.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Review top news and interview highlights from the week ending May 9, 2025.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Review top news and interview highlights from the week ending May 2, 2025.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Review top news and interview highlights from the week ending April 25, 2025.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Tami John, MD and Shalini Shenoy, MD, MBBS, offer insight into the clinical experience of patients treated with Casgevy and Zynteglo thus far.
Renier Brentjens, MD, PhD, the chair of the department of medicine at Roswell Park Comprehensive Cancer Center, discussed the need to bring more innovations from nonclinical research to patients.
Renier Brentjens, MD, PhD, the chair of the department of medicine at Roswell Park Comprehensive Cancer Center, discussed his views on toxicities and costs associated with CAR-T, and when and how the field should address them.
Review top news and interview highlights from the week ending April 18, 2025.
Renier Brentjens, MD, PhD, the chair of the department of medicine at Roswell Park Comprehensive Cancer Center, discussed his view on how the cell therapy field should proceed with regard to innovation.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Renier Brentjens, MD, PhD, the chair of the department of medicine at Roswell Park Comprehensive Cancer Center, discussed the innovations necessary to make CAR-T therapy effective in solid tumor indications.
Review top news and interview highlights from the week ending April 11, 2025.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
